Curated News
By: NewsRamp Editorial Staff
October 08, 2025
TransCode Acquires Polynoma, Secures $25M for Cancer Pipeline Expansion
TLDR
- TransCode's acquisition of Polynoma and $25M funding creates a unique oncology pipeline with Phase 3-ready melanoma vaccine and Phase 2 RNA therapeutic candidate.
- TransCode acquired Polynoma for its seviprotimut-L melanoma vaccine while securing $25M from CK Life Sciences to fund TTX-MC138 through Phase 2 trials.
- This acquisition advances treatments for metastatic cancer patients by combining late-stage melanoma vaccines with innovative RNA therapeutics targeting metastasis.
- TransCode's oncology pipeline now includes a Phase 3-ready melanoma vaccine alongside RNA therapeutics targeting microRNA-10b, a unique biomarker of metastasis.
Impact - Why it Matters
This development represents a significant advancement in cancer treatment innovation, particularly for patients with aggressive forms of melanoma and metastatic disease. The combination of TransCode's RNA therapeutic platform with Polynoma's late-stage melanoma vaccine creates a powerful pipeline that could potentially address critical unmet medical needs in oncology. For investors, this strategic acquisition and substantial funding demonstrate TransCode's growth trajectory and commitment to advancing multiple promising cancer therapies simultaneously. The broader medical community benefits from the potential emergence of new treatment options for stage IIB and IIC melanoma patients, while the successful development of these therapies could fundamentally change how metastatic cancers are treated, offering hope to millions affected by these devastating diseases worldwide.
Summary
TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage oncology company focused on treating metastatic disease, has made a significant strategic move by entering into a definitive agreement to acquire Polynoma LLC, a privately held immuno-oncology company. This acquisition brings seviprotimut-L, a late-stage polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma, into TransCode's portfolio. Concurrent with this acquisition, TransCode secured a substantial $25 million investment from CK Life Sciences Int'l (Holdings) Inc., providing crucial funding to advance its lead microRNA candidate, TTX-MC138, through a Phase 2 clinical trial. The company also announced leadership changes, with Philippe Calais, PharmD, PhD, appointed as Chief Executive Officer, succeeding Interim CEO Tom Fitzgerald, who returns to his role as Chief Financial Officer.
Dr. Calais emphasized the strategic importance of this acquisition, stating that it enables TransCode to create a unique and broader oncology pipeline combining the Phase 3-ready seviprotimut-L with their TTX-MC138 program. These assets position the company to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease. TransCode's proprietary TTX nanoparticle platform forms the foundation of their approach to defeating cancer through intelligent design and effective delivery of RNA therapeutics. The company's lead candidate, TTX-MC138, specifically targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis, while their broader portfolio aims to overcome RNA delivery challenges and unlock access to novel genetic targets relevant to treating various cancers. Additional information about TransCode Therapeutics and their innovative approaches can be found through the InvestorBrandNetwork's comprehensive coverage of the company's developments and strategic initiatives.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Acquires Polynoma, Secures $25M for Cancer Pipeline Expansion
